Company / Free Cash Flow per Share
Summit Therapeutics Inc. Free Cash Flow per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$0.43
FY2025
5-year range
-$0.74 / -$0.20
FY2021-FY2025
Trend
-113.5%
vs FY2024
Sector context
#83 of 192
Health Care
What the data says
At $-0.43, Summit Therapeutics Inc.'s free cash flow per share ranks #83 of 192 in the Health Care sector. Free Cash Flow per Share has fluctuated over the past 8 years, ranging from $-2.05 in FY2018 to $-0.20 in FY2024.
Based on SEC 10-K filings.
-0.43 in FY2025.
Declined from $-0.36 to $-0.43 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#83 of 192 in Health CareTop 43% of 192This company -$0.43 Sector average -$19.84
▼
+97.8% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share decreased 113.5% year-over-year.
- Ranks #83 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2024.
- Lowest free cash flow per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.43 | -113.5% |
| FY2024 | -$0.20 | +44.3% |
| FY2023 | -$0.36 | +51.0% |
| FY2022 | -$0.74 | -242.9% |
| FY2021 | -$0.22 | +70.0% |
| FY2020 | -$0.72 | -13.1% |
| FY2019 | -$0.64 | +68.8% |
| FY2018 | -$2.05 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026